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In most established tumors, incoming 
monocytes are “educated” by the tumor 
microenvironment to differentiate into 
macrophages exhibiting an M2-like func-
tional polarization and hence exerting a 
number of tumor-supporting functions. 
Indeed M2 macrophages have been shown 
to promote tumor cell proliferation and 
survival, support metastatic dissemina-
tion, stimulate angiogenesis and secrete 
extracellular matrix-remodeling enzymes. 
Strategies to deplete tumor-associated 
macrophages (TAMs) or to inhibit their 
recruitment to neoplastic lesions have been 
successful in experimental settings and are 
now considered as a promising therapeutic 
approach in the clinics.1-6
Trabectedin is an anticancer agent 
licensed in Europe and several other 
countries for the second-line treatment 
of soft tissue sarcoma patients and ovar-
ian carcinoma patients, in combination 
with liposomal doxorubicin.7-9 Originally 
extracted from a marine organism, the 
tunicate Ecteinascidia, it is now syntheti-
cally produced by the Spanish company 
PharmaMar and is the first marine anti-
neoplastic agent to reach marketing.
Trabectedin was initially identified 
for its potent cytotoxic activity against 
malignant cells. Trabectedin kills indeed 
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cancer cells and blocks their proliferation 
by interacting with DNA. Further studies 
clarified that the mechanism of action of 
this compound is more complex than that 
of a conventional cytotoxic agent, as tra-
bectedin affects DNA repair mechanisms 
as well as the activity of specific transcrip-
tion factors. With the idea of investigating 
the effects of trabectedin on non-prolifer-
ating cells, we tested it on human circulat-
ing monocytes and surprisingly observed 
that these cells succumbed to trabectedin 
in 48 h via caspase-dependent apoptosis.10 
We next observed that only monocytes and 
macrophages, among all leukocytes, were 
susceptible to the cytotoxic effects of tra-
bectedin, a finding that prompted a series 
of experiments to understand the exquisite 
selectivity of this agent for mononuclear 
phagocytes. We eventually demonstrated 
that trabectedin rapidly (within few hours) 
triggers the activation of caspase-8 down-
stream of plasma membrane tumor necrosis 
factor (TNF)-related apoptosis-inducing 
ligand (TRAIL) receptors (TRAIL-Rs), 
and that distinct leukocyte subsets express 
different sets of TRAIL-Rs. In particular, 
monocytes/macrophages mainly express 
signaling-proficient TRAIL-Rs, while neu-
trophils and T lymphocytes preferentially 
express signaling-incompetent TRAIL-Rs, 
which are unable to mediate caspase-8 
activation in response to agonists, and 
hence are resistant to trabectedin.10
The real issue was to investigate whether 
trabectedin would be able to kill mononu-
clear phagocytes in vivo and in the context 
of cancer. In different mouse tumor mod-
els, trabectedin significantly decreased the 
number of circulating monocytes as well as 
that of splenic macrophages and TAMs, but 
had no effect on neutrophils and lympho-
cytes. To prove that the cytotoxic activity of 
trabectedin on mononuclear phagocytes is 
relevant for its antitumor activity, we took 
advantage of a trabectedin-resistant tumor 
cell line. Mice bearing trabectedin-resistant 
tumors were indeed normally sensitive to 
the antitumor activity of trabectedin, in 
spite of the fact that the same cancer cells 
exhibited a pronounced resistance against 
the drug in vitro.10 We therefore hypoth-
esized that trabectedin exerts major inhibi-
tory effects on TAMs. In line with this 
interpretation, the adoptive transfer of mac-
rophages to trabectedin-treated mice signif-
icantly reinstated tumor growth. Thus, the 
targeting of macrophages in vivo is a key 
component of the antitumor activity of tra-
bectedin. Nevertheless, effects other than 
macrophage depletion may also contribute 
to the pronounced antineoplastic potential 
tumor-associated macrophages (tAMs) and other myeloid cells that infiltrate neoplastic lesions promote tumor 
progression and are associated with poor patient prognosis. we have recently demonstrated that trabectedin, a 
licensed and commercially available anticancer agent, is selectively cytotoxic for tAMs and their circulating precursors 
(monocytes). the macrophage-depleting effect of trabectedin is a key component of its antitumor activity.
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Several questions remain to be 
addressed. First, does trabectedin inde-
pendently affect the vessel network or 
does this effect stem from the trabecte-
din-induced reduction of pro-angiogenic 
macrophages? Of note, the macrophage-
depleting agent clodronate also inhibits 
tumor growth in mice (although with a 
less durable effect) but does not appear 
to influence the tumor-associated vascu-
lature. Second, is the monocyte-selective 
cytotoxicity of trabectedin similar in 
all patients or may individual variabil-
ity influence the therapeutic efficacy of 
the drug? A number of pharmacological 
agents are being studied for their abil-
ity to modulate TRAIL-R expression by 
neoplastic cells, and hence their suscep-
tibility to recombinant TRAIL. Finally, 
it would be interesting to investigate the 
feasibility of combination therapies aimed 
at maximize the effects of trabectedin on 
myelomonocytic (and perhaps tumor) 
cells. Along similar lines, the combination 
of trabectedin with anti-angiogenic drugs 
may result in improved clinical responses, 
as it is now well established that TAMs 
are often responsible for the resistance to 
these agents.
In summary, our findings delineated 
a new mechanism of action of a clini-
cally useful and commercially available 
anticancer agent while providing strong 
proof-of-concept evidence in support of 
the therapeutic targeting of macrophages 
in cancer patients. Trabectedin is cur-
rently used in a limited number of onco-
logical indications, often as second-line 
treatment. Our results open interesting 
perspectives for the rational exploitation 
of this peculiar agent in cancer therapy.
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soft tissue sarcomas receiving trabectedin 
as a standalone therapeutic intervention. 
In this setting, a decrease in blood mono-
cytes was documented in most patients 
within a few days after the injection of 
trabectedin.10 Furthermore, in tumor 
sections collected before and after neo-
adjuvant therapy, a dramatic decrease in 
infiltrating macrophages and vessel den-
sity was observed, reinforcing the notion 
that trabectedin strikes both the neo-
plastic cell compartment and the tumor 
microenvironment.
of this drug. Immunohistochemical stud-
ies on tumor sections revealed indeed 
that trabectedin significantly reduces the 
expression levels of the angiogenic mediator 
vascular endothelial growth factor (VEGF) 
and the chemokine CCL2 in tumor ves-
sels.10 Thus, besides direct killing mononu-
clear phagocytes, trabectedin may limit the 
recruitment of circulating monocytes into 
neoplastic lesions and inhibit angiogenesis 
(Fig. 1).
The abundance of circulating mono-
cytes was studied in patients affected by 
Figure 1. Mechanisms of action of trabectedin. the marine anticancer agent trabectedin is cyto-
toxic for tumor-associated macrophages (tAMs) and neoplastic cells. By inhibiting the production 
of the chemokine CCL2 trabectedin also decreases monocyte recruitment in tumors. the effects 
of trabectedin on the tumor microenvironment are important for its antitumor activity.
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